Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2012. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in their interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to insider trading disclosures and does not contain financial performance data.
Material Changes
No material changes to the company's financial position or operations are reported in this document. The only changes disclosed relate to the shareholdings of specific individuals:
- Sir Andrew Witty: Exercised a SAYE share option to purchase 1,009 Ordinary shares at £9.51 per share. Transferred 759 shares into an ISA at £14.0575 per share. Gifted 500 shares to each of his two children.
- Mr S M Bicknell: Exercised a SAYE share option to purchase 1,009 Ordinary shares at £9.51 per share. Transferred 759 shares into an ISA at £14.0575 per share.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly adheres to Disclosure Rule 3.1.4R(1)(a) and (c) regarding director transactions.
Investor Verification Points
- Verify the total number of shares held by Sir Andrew Witty and Mr S M Bicknell following these transactions.
- Confirm the market price of GSK Ordinary Shares on February 7, 2012, to assess the value of the ISA transfers and gifts.
- Review the terms of the Sharesave Plan granted on December 1, 2008, to understand the vesting conditions for the exercised options.